Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers

Bravermanová, Anna; Viktorinová, Michaela; Tylš, Filip; Novák, Tomáš; Androvičová, Renáta; Korčák, Jakub; Horáček, Jiří; Balı́ková, Marie; Griškova-Bulanova, Inga; Danielová, Dominika; Vlček, Přemysl; Mohr, Pavel; Brunovský, Martin; Koudelka, Vlastimil; Páleníček, Tomáš

doi:10.1007/s00213-017-4807-2

Cited by 36 publications

(23 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High dose psilocybin reduces attention to both clinical and electrophysiological parameters. However, this may be due to an increased awareness of sensory stimuli that are usually filtered out (cost of attention) rather than reduced attentional ability per se (Carter et al, 2005;Bravermanová et al, 2018).…”

Section: Cognitive Effectsmentioning

confidence: 99%

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Jones

O'Kelly

2020

Front. Synaptic Neurosci.

View full text Add to dashboard Cite

Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic changes and reduce neuroinflammation. This inevitably makes them interesting candidates for therapeutics in dementia. This mini-review will look at the basic science and current clinical evidence for the role of psychedelics in treating dementia, especially early AD, with a particular focus on microdosing of the classical psychedelics LSD and psilocybin.

show abstract

Section: Cognitive Effectsmentioning

confidence: 99%

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Jones

O'Kelly

2020

Front. Synaptic Neurosci.

View full text Add to dashboard Cite

show abstract

“…Disturbed cognitive processing related to psychosis as indicated by the P3 has further been investigated in the context of psychedelic drugs. Application of psilocybin to healthy subjects induced psychotic-like symptoms and a disrupted auditory P3 that decreased with increasing intensity of the psychedelic status (Bravermanová et al 2018). In previous moderate and heavy MDMA consumers, reduced P3 amplitudes in a visual discrimination task even 6 months after last drug intake indicate long lasting impairments in cognitive performance (Casco et al 2005).…”

Section: P3mentioning

confidence: 99%

Biomarkers and neuromodulation techniques in substance use disorders

et al. 2020

View full text Add to dashboard Cite

Addictive disorders are a severe health concern. Conventional therapies have just moderate success and the probability of relapse after treatment remains high. Brain stimulation techniques, such as transcranial Direct Current Stimulation (tDCS) and Deep Brain Stimulation (DBS), have been shown to be effective in reducing subjectively rated substance craving. However, there are few objective and measurable parameters that reflect neural mechanisms of addictive disorders and relapse. Key electrophysiological features that characterize substance related changes in neural processing are Event-Related Potentials (ERP). These high temporal resolution measurements of brain activity are able to identify neurocognitive correlates of addictive behaviours. Moreover, ERP have shown utility as biomarkers to predict treatment outcome and relapse probability. A future direction for the treatment of addiction might include neural interfaces able to detect addiction-related neurophysiological parameters and deploy neuromodulation adapted to the identified pathological features in a closed-loop fashion. Such systems may go beyond electrical recording and stimulation to employ sensing and neuromodulation in the pharmacological domain as well as advanced signal analysis and machine learning algorithms. In this review, we describe the state-of-the-art in the treatment of addictive disorders with electrical brain stimulation and its effect on addiction-related neurophysiological markers. We discuss advanced signal processing approaches and multi-modal neural interfaces as building blocks in future bioelectronics systems for treatment of addictive disorders.

show abstract

“…Case reports and clinical trials have also shown a potential in the treatment of OCD (Brandrup & Vanggaard, 1977). In one patient, symptom relief persisted for a period of 5 months following a single dose (Leonard & Rapoport, 1987;Moreno, Wiegand, Taitano, & Delgado, 2006).…”

Section: Use Of Psychedelics In Contemporary Medicinementioning

confidence: 99%

“…The Czech Republic remains in the forefront of psychedelic science even todaythe Czech National Institute of Mental Health is currently conducting a clinical trial on psilocybin as a model of psychosis. To date, psilocybin has been administered to 20 healthy volunteers (Bravermanová et al, 2018). Moreover, a new multicenter research sponsored by Compass Pathways will study the use of psilocybin in a new sample of patients with treatment-resistant depression.…”

Section: Introductionmentioning

confidence: 99%

Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?

Postránecká¹,

Vejmola

Tylš

2019

Journal of Psychedelic Studies

Self Cite

View full text Add to dashboard Cite

Psychedelic research has been associated with the Czech Republic since the early 19th century and, after a long period of involuntary dormancy, it has recently gained new opportunities to follow up on its roots and evolve. This article briefly describes the history of psychedelic research in the Czech Republic, summarizes the role of the UN Drug Conventions, and discusses the Czech and international legislation pertaining to psychedelics. The discussion focuses on the dependence/abuse potential of classical psychedelics, their medical use, and their safety in medical versus non-medical environment. Despite the assertions of the UN and occasional media disinformation about the dangers of psychedelics, recent investigations have shown that classical psychedelics are not addictive, show great promise in a broad spectrum of medical uses, and have been repeatedly proven to be safe in a clinical setting. Finally, the authors suggest a procedure for the preparation and implementation of controlled psychedelic therapy in the Czech medical and legal system.

show abstract

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers

Cited by 36 publications

References 78 publications

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Biomarkers and neuromodulation techniques in substance use disorders

Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?

Contact Info

Product

Resources

About